Posted On: 08/29/2014 9:35:26 PM
Post# of 30067
Re: Daveludlow #4993
Dave you state the obvious - of which most eyes are clearly fixated on - all with good cause:
IMHO, LymPro alone is worth a FMV of $350-Mil. to $500-Mil. in its current state of development = $0.48 to $0.68 pps, with 730-Mil. OS shares.
My direction is with alternatives - not so well exposed:
1.) IND for MANF RP or Wolframs DB-1
2.) final GMP Manufacturer for MANF revealed
3.) Novartis behind the scenes work on MANF DB-2 - huge JV potential
4.) PhenoGuard - partnering business model disclosure - J&J as favored choice
5.) new neurotrophic factor discovery
6.) additional undisclosed initiatives on MANF
Coupled with anticipated LymPro and Eltroprazene news - any/all of the above have the ability to move the pps to unchartered share price territory...
All the Best, JP
Quote:
3 LymPro catalysts:
1) Revenue Guidance
2) Data
3) Partnership
IMHO, LymPro alone is worth a FMV of $350-Mil. to $500-Mil. in its current state of development = $0.48 to $0.68 pps, with 730-Mil. OS shares.
My direction is with alternatives - not so well exposed:
1.) IND for MANF RP or Wolframs DB-1
2.) final GMP Manufacturer for MANF revealed
3.) Novartis behind the scenes work on MANF DB-2 - huge JV potential
4.) PhenoGuard - partnering business model disclosure - J&J as favored choice
5.) new neurotrophic factor discovery
6.) additional undisclosed initiatives on MANF
Coupled with anticipated LymPro and Eltroprazene news - any/all of the above have the ability to move the pps to unchartered share price territory...
All the Best, JP
(0)
(0)
